Paliroden

Paliroden
Clinical data
Other namesSR-57667; SR57667; SR-57667B; SR57667B
Routes of
administration
Oral
ATC code
  • None
Identifiers
  • 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H24F3N
Molar mass407.480 g·mol−1
3D model (JSmol)
  • C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4
  • InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2
  • Key:CNEWKIDCGDXBDE-UHFFFAOYSA-N

Paliroden (INNTooltip International Nonproprietary Name; developmental code names SR-57667 and SR-57667B) is a drug which was under development for the treatment of Alzheimer's disease and Parkinson's disease but was never marketed. It is taken orally. The exact mechanism of action of the drug does not appear to have been disclosed, but it has been found to stimulate neurogenesis in preclinical research. It was under development by sanofi-aventis. Paliroden reached phase 2 clinical trials for Alzheimer's disease and Parkinson's disease prior to the discontinuation of its development in 2007. It is an analogue and follow-on drug of xaliproden (SR-57746; SR-57746A), which is a serotonin 5-HT1A receptor agonist and neurogenesis stimulant that reached phase 3 trials for similar indications but also did not complete development.

See also